(Updated - April 10, 2026 4:04 PM EDT)
Seaport Therapeutics on Friday submitted a registration statement to pursue a proposed initial public offering on the Nasdaq exchange.
The company describes its mission as discovering and developing medicines for depression, anxiety and other severe neuropsychiatric disorders. Seaport characterizes itself as a clinical-stage therapeutics company that focuses on translating clinically validated mechanisms into oral treatments where earlier attempts were constrained by high first-pass metabolism, poor bioavailability, or undesirable side effects.
A central component of Seaports stated approach is its Glyph platform. According to the filing, Glyph is a lymphatic-targeting prodrug technology engineered to bypass first-pass metabolism, with the intended effects of improving a drugs oral bioavailability and lowering side effects. The company refers to the process of applying the technology as "Glyphing," and says this work also generates new composition-of-matter intellectual property.
Seaport emphasized that its leadership team comprises industry veterans with experience in neuropsychiatry drug discovery and development, and said the organization aims to deliver novel treatment options that will meaningfully affect patients and families.
Investment banks named to manage the offering are Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel, which will serve as underwriters for the proposed IPO.
Context and next steps
The filing initiates the formal process toward a public debut but does not by itself set offering size, share pricing, or a definitive timetable. Those details will be established later in the registration process and in coordination with the underwriters.
What is known from the filing:
- Seaport Therapeutics has filed for a proposed Nasdaq IPO.
- The company is clinical-stage and focused on treatments for depression, anxiety and other neuropsychiatric conditions.
- Seaport promotes a proprietary Glyph lymphatic-targeting prodrug platform intended to bypass first-pass metabolism and enhance oral bioavailability while reducing side effects.
- Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel are named as underwriters.
Further developments will depend on subsequent disclosures in the registration process and on decisions by the company and its underwriting syndicate.